期刊文献+

人参α-淀粉酶抑制肽的降血糖作用

Hypoglycemic Effects of Ginsengα-Amylase Inhibitory Peptides
下载PDF
导出
摘要 通过采用高糖高脂饲料联合腹腔注射链脲佐菌素(Streptozotocin,STZ)构建小鼠2型糖尿病(Type 2 Diabetes,T2DM)模型,建模成功后连续4周给药治疗T2DM小鼠,以小鼠体质量、脏器指数、血糖、血脂、肝脏氧化应激反应、肝脏病理学检验结果作为参考指标,探究人参α-淀粉酶抑制肽对T2DM小鼠的降糖作用。结果表明,阿卡波糖阳性组和人参α-淀粉酶抑制肽各剂量组对小鼠的体重下降情况、高血糖情况均有不同程度的改善作用及调控效果,所以人参α-淀粉酶抑制肽各个剂量对T2DM小鼠具有降糖的效果。经过4周的治疗,高剂量组血糖从建模后的15.43 mmol/L下降至12.10 mmol/L与阿卡波糖阳性组血糖从建模后的15.71 mmol/L下降至10.17 mmol/L结果相近,且两组的小鼠肝脏损伤较轻,说明高剂量的人参α-淀粉酶抑制肽对2型糖尿病引发的肝脏损伤可起到明显的防护效果(P<0.01)。因此,人参α-淀粉酶抑制肽具有降血糖的作用和成为辅助治疗2型糖尿病产品或保健品的潜力。 Mouse models of type 2 diabetes mellitus(T2DM)were constructed using a high-sugar and high-fat diet combined with an intraperitoneal injection of streptozotocin(STZ).After successful modeling,T2DM mice were treated with drugs for four consecutive weeks.The body weight,organ index,blood glucose level,blood lipid level,hepatic oxidative stress response,and pathology test results of the liver were used as reference indicators to investigate the hypoglycemic effects of ginsengα-amylase inhibitory peptides on T2DM mice.The results showed that the acarbose positive group and the ginsengα-amylase inhibitory peptide groups(regardless of the dose)exhibited improvement and regulatory effects of different degrees in the body weight loss and hyperglycemia in mice.Furthermore,the effects were more obvious as the dose increased.Therefore,it was concluded that ginsengα-amylase inhibitory peptides have hypoglycemic effects on T2DM mice at all doses tested.After four weeks of treatment,the blood glucose level in the high-dose group decreased from 15.43 mmol/L right after modeling to 12.10 mmol/L.Similarly,the level in the acarbose-positive group declined from 15.71 mmol/L after modeling to 10.17 mmol/L.In addition,liver injury in both groups was less severe,indicating that a high dose of ginsengα-amylase inhibitory peptides could provide significant protection against T2DM-induced liver injury(P<0.01).Hence,ginsengα-amylase inhibitory peptides were confirmed to have hypoglycemic effects proving their potential as dietary supplements or supplementary products for the treatment of T2DM.
作者 杨雯 邹佳琪 刘胜楠 刘士伟 薛婷芳 孟星坚 于雷 詹晓峰 毕云枫 YANG Wen;ZOU Jiaqi;LIU Shengnan;LIU Shiwei;XUE Tingfang;MENG Xingjian;YU Lei;ZHAN Xiaofeng;BI Yunfeng(College of Food Science and Engineering,Jilin Agricultural University,Changchun 130118,China;Jilin Hongjiu Biotechnology Co.Ltd.,Tonghua 135118,China)
出处 《现代食品科技》 CAS 北大核心 2024年第7期24-34,共11页 Modern Food Science and Technology
基金 吉林省科技厅重点研发项目(20210204179YY)。
关键词 人参α-淀粉酶抑制肽 降血糖 2型糖尿病 链脲佐菌素 人参 ginsengα-amylase inhibitory peptide hypoglycemic type 2 diabetes streptozotocin ginseng
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部